GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects
Everyone I know on this medication ends up obese, diabetic, and with high cholesterol
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinsons disease
doi: 10.1124/jpet.102.037481 192 QiuCWangYPPanXDLiuXYChenZLiuLB
Submission of the drug for FDA approval for weight loss is expected after completion of a second phase 3 trial, SURMOUNT-2, in spring 2023
Semaglutide (Ozempic, Wegovy, Rybelsus) If GLP-1 medications had a fan-favorite, semaglutide would be the one everyones talking about